MXPA04006039A - Methods for the treatment of peripheral neural and vascular ailments. - Google Patents

Methods for the treatment of peripheral neural and vascular ailments.

Info

Publication number
MXPA04006039A
MXPA04006039A MXPA04006039A MXPA04006039A MXPA04006039A MX PA04006039 A MXPA04006039 A MX PA04006039A MX PA04006039 A MXPA04006039 A MX PA04006039A MX PA04006039 A MXPA04006039 A MX PA04006039A MX PA04006039 A MXPA04006039 A MX PA04006039A
Authority
MX
Mexico
Prior art keywords
treatment
methods
ailments
compositions
peripheral neural
Prior art date
Application number
MXPA04006039A
Other languages
Spanish (es)
Inventor
Richard A Rosenbloom
Original Assignee
The Quigley Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2001/049297 external-priority patent/WO2002049575A2/en
Application filed by The Quigley Corp filed Critical The Quigley Corp
Publication of MXPA04006039A publication Critical patent/MXPA04006039A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A61K8/355—Quinones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)

Abstract

Compositions and methods for the treatment of peripheral neuraland vascular ailments are disclosed. The method comprises administering a flavonoid compound with antioxidant properties, optionally formulated in a pharmaceutically acceptable carrier. This compound or combination of compounds provides significant, effective relief of the symptoms of peripheral neural or vascular ailments. In addition, the compositions, when used according to the methods of the present invention, do not exhibit the severe side effects of many prior art compositions proposed for treatment of these ailments.
MXPA04006039A 2001-12-19 2002-11-06 Methods for the treatment of peripheral neural and vascular ailments. MXPA04006039A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2001/049297 WO2002049575A2 (en) 2000-12-21 2001-12-19 Method and composition for the treatment of diabetic neuropathy
PCT/US2002/035654 WO2003053336A2 (en) 2001-12-19 2002-11-06 Methods for the treatment of peripheral neural and vascular ailments

Publications (1)

Publication Number Publication Date
MXPA04006039A true MXPA04006039A (en) 2004-09-27

Family

ID=21743140

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04006039A MXPA04006039A (en) 2001-12-19 2002-11-06 Methods for the treatment of peripheral neural and vascular ailments.

Country Status (8)

Country Link
EP (1) EP1455778A4 (en)
JP (1) JP2005518381A (en)
CA (1) CA2470603A1 (en)
IL (1) IL162505A0 (en)
MX (1) MXPA04006039A (en)
NZ (1) NZ533439A (en)
WO (1) WO2003053336A2 (en)
ZA (1) ZA200404614B (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5044122B2 (en) * 2003-10-24 2012-10-10 株式会社明治 Novel inhibitors of late glycation end product formation and aldose reductase inhibitors
CA2543676C (en) * 2003-10-30 2011-04-26 Meiji Seika Kaisha, Ltd. Tyrosinase activity inhibitor and ameliorant for facial blood flow
WO2005046584A2 (en) * 2003-11-05 2005-05-26 Osteoscreen, Inc. Stimulation of hair growth by ginkgo biloba flavanoids
JP2006083105A (en) * 2004-09-16 2006-03-30 Ito En Ltd Ameliorant for blood fluidity and food and beverage
ZA200800266B (en) * 2005-06-28 2009-08-26 Kgk Synergize Inc Compositions to improve the bioavailability of polymethoxyflavones and tocotrienols for the treatment of cardiovascular disease
DE102005048777A1 (en) * 2005-10-10 2007-04-12 Beiersdorf Ag Cosmetic formulations to improve the microcirculation of the skin
DE102005048778A1 (en) * 2005-10-10 2007-04-12 Beiersdorf Ag Cosmetic formulations to improve the appearance of the skin
JP5132889B2 (en) * 2006-02-27 2013-01-30 株式会社ポッカコーポレーション Nerve growth factor potentiator
WO2007117494A1 (en) * 2006-04-05 2007-10-18 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
FR2904557B1 (en) * 2006-08-01 2010-04-30 Pf Medicament NOVEL EUCALYPTUS EXTRACT, PREPARATION METHOD THEREOF AND THERAPEUTIC USES THEREOF
GB0618168D0 (en) * 2006-09-15 2006-10-25 Babraham Inst Compounds
US20090060879A1 (en) * 2007-09-04 2009-03-05 The Procter & Gamble Company Oral Compositions, Products and Methods Of Use
KR20110033304A (en) * 2008-07-23 2011-03-30 메사추세츠 인스티튜트 오브 테크놀로지 Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival
JP5415216B2 (en) * 2009-10-02 2014-02-12 日本メナード化粧品株式会社 Topical skin preparation
CN102266320B (en) * 2010-07-20 2015-06-17 浙江养生堂天然药物研究所有限公司 New application of hesperetin
KR101021835B1 (en) 2010-09-06 2011-03-17 충남대학교산학협력단 A composition comprising chrysosplenol c for treating and preventing heart disease
CN102151281B (en) * 2011-01-24 2014-03-26 中国药科大学 Flavonoid compound for preventing and treating diabetes and medicament application thereof
EP3483150A1 (en) 2011-07-22 2019-05-15 Massachusetts Institute Of Technology Activators of class 1 histone deacetylases (hdacs) and uses thereof
NZ596015A (en) * 2011-10-26 2014-04-30 Anzamed Internat Ltd Method and composition for the treatment of pain and/or inflammation
CN102526248B (en) * 2012-03-22 2013-07-17 赵海潞 Traditional Chinese medicine prescription capable of curing diabetes wound fester and continuously reducing blood sugar
US20180193306A1 (en) 2012-03-23 2018-07-12 Cardero Therapeutics, Inc. Compounds and compositions for the treatment of muscular disorders and bone disorders
WO2013142816A1 (en) * 2012-03-23 2013-09-26 Cardero Therapeutics, Inc. Compounds and compositions for the treatment of muscular disorders
ITRM20120335A1 (en) * 2012-07-13 2014-01-14 Aboca Spa Societa Agricola NEW COMPOSITIONS FOR NEUROPATHIC PAIN TREATMENT.
WO2014095289A2 (en) * 2012-12-20 2014-06-26 Unilever Plc Method of treating hair ageing
US9844531B2 (en) 2013-03-15 2017-12-19 Abbott Laboratories Methods of maintaining and improving muscle function
CN104547872A (en) * 2015-01-30 2015-04-29 山东省立医院 Traditional Chinese medicine composition for treating epilepsy
CN107126437A (en) * 2016-02-29 2017-09-05 上海中医药大学 A kind of medicinal usage of Sophoricoside
KR101828379B1 (en) 2016-03-30 2018-02-12 우석대학교 산학협력단 Compositions for the improvement of memory and cognition ability, or prevention, delay, improvement or treatment of Alzheimer's disease comprising Rosa rugosa THUNB flower extracts or fractions
KR101715294B1 (en) * 2016-06-09 2017-03-10 연세대학교 산학협력단 Composition having effects of skin moisturizing, exfoliating, improving skin elasticity, inhibiting erythema, anti-wrinkle or improving skin photoaging comprising diosmin or salt thereof
WO2018078412A1 (en) * 2016-10-31 2018-05-03 Posi Visionary Solutions Llp Topical microemulsion of diosmetin and uses thereof
CN108164489B (en) * 2018-03-20 2019-11-26 武汉轻工大学 A kind of preparation method of Galangin
BR102018005599A2 (en) * 2018-03-21 2019-10-08 Pedro Barboza Da Rocha HAZARDOUS, HYDRATING, MOISTURIZING AND EMOLIENT COMPOSITION FOR TOPIC ADMINISTRATION IN INTERTRIGO SKIN INJURIES, SKIN INJURY AND FECAL INJURY AND OTHER RELATED INJURY.
WO2020051644A1 (en) * 2018-09-13 2020-03-19 Norbio No. 2 Pty Ltd Treatment of peripheral nervous tissue inflammation
CN112014480B (en) * 2019-05-28 2023-03-28 黄河科技学院 Method for detecting content of effective components in Jiangzhining granules by UPLC-MS/MS
WO2022157381A1 (en) * 2021-01-25 2022-07-28 Universiteit Hasselt Phloretin for use in the treatment of neurodegenerative and demyelinating diseases
CN115317497A (en) * 2022-01-13 2022-11-11 宁夏医科大学 Application of liquiritin in preparing thoracic aorta vasodilation medicine
CN114392256B (en) * 2022-02-22 2023-05-09 中山大学附属第八医院（深圳福田） Application of cyanidin in preventing and treating vascular calcification
WO2024112947A1 (en) * 2022-11-23 2024-05-30 Brightseed, Inc. Compositions and methods for modulating sleep and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03232851A (en) * 1989-12-26 1991-10-16 Nippon Flour Mills Co Ltd Aldose reductase inhibitor
JPH09235284A (en) * 1995-02-23 1997-09-09 Nissan Chem Ind Ltd Indole-type thiazolidine compound
IT1291113B1 (en) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti NUTRITIONAL THERAPEUTIC COMPOSITION FOR SUBJECTS WITH DIABETES MELLITUS
IT1302307B1 (en) * 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa COMPOSITION WITH ANTIOXIDANT ACTIVITY AND FOR IMPROVING THE METABOLIC USE OF GLUCOSE, INCLUDING ACETYL
JP4497566B2 (en) * 1998-09-02 2010-07-07 株式会社 日本薬用食品研究所 Aldose reductase inhibitors and novel saponins and novel sapogenols
US20030203857A1 (en) * 2000-04-11 2003-10-30 Hiromu Ohnogi Remedies
EP1351679B1 (en) * 2000-12-21 2010-02-03 The Quigley Corporation Method and composition for the treatment of diabetic neuropathy

Also Published As

Publication number Publication date
EP1455778A2 (en) 2004-09-15
AU2002352501A1 (en) 2003-07-09
WO2003053336A2 (en) 2003-07-03
JP2005518381A (en) 2005-06-23
IL162505A0 (en) 2005-11-20
WO2003053336A3 (en) 2003-11-27
EP1455778A4 (en) 2007-09-12
NZ533439A (en) 2006-06-30
CA2470603A1 (en) 2003-07-03
ZA200404614B (en) 2005-08-29

Similar Documents

Publication Publication Date Title
MXPA04006039A (en) Methods for the treatment of peripheral neural and vascular ailments.
IL267381A (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
EP3530288A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
WO2002085303A3 (en) Substituted tetracycline compounds for the treatment of malaria
WO2004052280A3 (en) Anti-angiogenic compounds and their use in cancer treatment
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
WO2001087306A8 (en) Compositions and methods for the treatment of colorectal cancer
WO2001087328A3 (en) Interleukin-1 inhibitors in the treatment of diseases
SG152907A1 (en) Combinations for the treatment of inflammatory disorders
CA2427227A1 (en) Lactam compound
AU2003297048A1 (en) Cyclohexyl compounds as ccr5 antagonists
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
WO2003020280A3 (en) Compositions and use thereof in the treatment of cancer
WO2004038001A3 (en) Substituted tetracycline compounds for the treatment of malaria
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
WO2003061566A3 (en) Anti-cancer combination and use thereof
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
EP1032556A4 (en) Pharmaceutically active compounds and methods of use
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
AU2002314056A1 (en) Use of a vitamin d3 analogue for the treatment of autoimmune diabetes
PL368737A1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
WO2003020371A3 (en) Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer
IL129267A (en) Pharmaceutical compositions comprising histamine and/or serotonin for treatment of urinary incontinence
AU5434899A (en) Cancer treatment

Legal Events

Date Code Title Description
FG Grant or registration